Abstract:Recent developments in tumor immunology and biotechnology have made cancer gene therapy and immunotherapy feasible. The current efforts for cancer gene therapy mainly focus on using immunogenes, chemogenes and tumor suppressor genes. Central to all these therapies is the development of efficient vectors for gene therapy. By far, adenovirus (AdV)-mediated gene therapy is one of the most promising approaches, as has confirmed by studies relating to animal tumor models and clinical trials. Dendritic cells (DCs) are highly efficient, specialized antigen-presenting cells, and DC-based tumor vaccines are regarded as having much potential in cancer immunotherapy. Vaccination with DCs pulsed with tumor peptides, lysates, or RNA, or loaded with apoptotic/necrotic tumor cells, or engineered to express certain cytokines or chemokines could induce significant antitumor cytotoxic T lymphocyte (CTL) responses and antitumor immunity. Although both AdV-mediated gene therapy and DC vaccine can both stimulate antitumor immune responses, their therapeutic efficiency has been limited to generation of prophylactic antitumor immunity against re-challenge with the parental tumor cells or to growth inhibition of small tumors. However, this approach has been unsuccessful in combating well-established tumors in animal models. Therefore, a major strategic goal of current cancer immunotherapy has become the development of novel therapeutic strategies that can combat well-established tumors, thus resembling real clinical practice since a good proportion of cancer patients generally present with significant disease. In this paper, we review the recent progress in AdV-mediated cancer gene therapy and DC-based cancer vaccines, and discuss combined immunotherapy including gene therapy and DC vaccines. We underscore the fact that combined therapy may have some advantages in combating well-established tumors vis-a-vis either modality administered as a monotherapy.

Recent Developments in the Use of Adenoviruses and Immunotoxins in Cancer Gene Therapy

Recent Developments in Gene Therapy and Immunotherapy

Recent advances in genetic modification of adenovirus vectors for cancer treatment

Adeno-associated Virus-Mediated Cancer Gene Therapy: Current Status.

Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).

Advance in Gene Therapy of Tumors

Progress in systemic administration of adenovirus vector for cancer gene therapy

Section Review—Oncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Advances in Research on Adenovirus Nanocomplexes for Tumor Therapy

Advancement and prospects of tumor gene therapy

Combinational Adenovirus-Mediated Gene Therapy and Dendritic Cell Vaccine in Combating Well-Established Tumors

Non-viral Gene Delivery for Cancer Immunotherapy.

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

Adenovirus as a Vector and Oncolytic Virus

Current developments of gene therapy in human diseases

Advancements of gene therapy in cancer treatment: A comprehensive review

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy